Table 1.
Anterograde and retrograde bowel preparation regimens studied in patients with inflammatory bowel disease
|
Ref.
|
Year
|
Design
|
n
|
IBD
|
Bowel preparation
|
Split dosing considered
|
Low fiber diet considered
|
Main result (success), %
|
Post-colonoscopy IBD flare-up rate, % (days after colonoscopy)
|
Severe AEs
|
| Gould et al[13] | 1982 | CT | 23 | UC: 23 | Castor oil 30 mL | - | YES | 82.6 | 26 (14-21 d) | NO |
| Gould et al[13] | 1982 | CT | 23 | UC: 23 | Sennosides 75 mg | - | YES | 86.9 | 48 (14-21 d) | NO |
| Lazzaroni et al[15] | 1993 | CT | 48 | UC: 26; CD: 23 | 4 L PEG-ELS plus placebo | YES | - | 96 | - | NO |
| Lazzaroni et al[15] | 1993 | CT | 57 | UC: 35; CD: 21 | 4 L PEG-ELS plus simethicone | YES | - | 96 | - | NO |
| Manes et al[53] | 2015 | CT | 106 | UC: 106 | 2 L PEG plus bisacodyl | YES | YES | 83 | - | NO |
| Manes et al[53] | 2015 | CT | 105 | UC: 105 | 4 L PEG-ELS | YES | YES | 77.1 | - | NO |
| Kim et al[22] | 2017 | CT | 53 | UC: 53 | 4 L PEG-ELS | YES | YES | 96.2 | 5.7 (7 d); 1.9 (28 d) | NO |
| Kim et al[22] | 2017 | CT | 56 | UC: 56 | 2 L PEG plus ascorbate | YES | YES | 92.9 | 3.6 (7 d); 1.8 (28 d) | NO |
| Briot et al[31] | 2019 | nCT Prospective | UC: 21; CD: 57; Unspecified IBD: 2 | Picosulphate-based regimen | YES | YES | 78.4 | 0 | NO | |
| Bezzio et al[39] | 2020 | nCTProspective | 189 | UC: 63; CD: 63 | 2 L PEG-ELS plus simethicone | YES | - | UC: 89.8; CD: 86.2 | - | NO |
| Maida et al[25] | 2021 | nCT Retrospective | 185 | UC: 95; CD: 90 | 1 L PEG plus ascorbate solution | YES | YES | 92.9 | - | NO |
| Mohsen et al[30] | 2021 | CT | 61 | - | 2 L Sodium; picosulphate, magnesium citrate PEG | YES | YES | 89.5 | - | NO |
| Mohsen et al[30] | 2021 | CT | 64 | - | 2 L PEG plus ascorbate solution | YES | YES | - | NO | |
| Neri et al[29] | 2021 | nCT Prospective | 103 | UC: 47; CD: 56 | 1 L PEG-ELS | YES | YES | 85.4 | - | NO |
| Kim et al[32] | 2022 | nCT Prospective | 52 | UC: 35; CD: 17 | 2 L PEG plus ascorbate | YES | YES | 98.1 | 0 (7 and 28 d) | NO |
| Kim et al[32] | 2022 | nCT Prospective | 55 | UC: 37; CD: 18 | Novel oral sulphate tablets | YES | YES | 98.1 | 3,63 (7 and 28 d) | NO |
| Gajera et al[51] | 2022 | nCT Retrospective | 318 | UC: 182; CD: 104; Unspecified IBD: 28 | Colonic lavage | Not applicable | YES | 97 | - | NO |
IBD: Inflammatory bowel disease; PEG: Polyethylene glycol; ELS: Electrolyte lavage solution; UC: Ulcerative colitis; CD: Crohn’s disease; CT: Clinical trial; nCT: Non-clinical trial.